Farther Finance Advisors LLC Has $5.37 Million Stake in Abbott Laboratories $ABT

Farther Finance Advisors LLC increased its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 19.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 39,491 shares of the healthcare product maker's stock after purchasing an additional 6,486 shares during the period. Farther Finance Advisors LLC's holdings in Abbott Laboratories were worth $5,371,000 at the end of the most recent quarter.

• Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield

Other large investors have also bought and sold shares of the company. Hughes Financial Services LLC acquired a new stake in Abbott Laboratories in the 1st quarter valued at approximately $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories in the first quarter worth $28,000. Elequin Capital LP acquired a new position in Abbott Laboratories during the first quarter worth $30,000. Wormser Freres Gestion acquired a new stake in Abbott Laboratories in the 4th quarter valued at $32,000. Finally, JCIC Asset Management Inc. bought a new stake in Abbott Laboratories during the 1st quarter worth about $32,000. 75.18% of the stock is owned by institutional investors.

Abbott Laboratories Stock Up 1.2%

ABT stock opened at $136.22 on Friday. Abbott Laboratories has a fifty-two week low of $110.86 and a fifty-two week high of $141.23. The stock has a fifty day moving average of $130.47 and a 200-day moving average of $131.14. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The company has a market capitalization of $237.09 billion, a price-to-earnings ratio of 17.07, a PEG ratio of 2.58 and a beta of 0.69.

• If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to analyst estimates of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.14 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Investors of record on Wednesday, October 15th will be given a dividend of $0.59 per share. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a dividend yield of 1.7%. Abbott Laboratories's payout ratio is currently 29.57%.

Wall Street Analyst Weigh In

• Tariff-Resistant Abbott Laboratories on Track for New Highs

A number of analysts recently issued reports on ABT shares. Royal Bank Of Canada lifted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the company an "outperform" rating in a research report on Tuesday, July 15th. Evercore ISI upped their price objective on Abbott Laboratories from $140.00 to $145.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 8th. Leerink Partners initiated coverage on shares of Abbott Laboratories in a research note on Monday, June 16th. They issued a "market perform" rating and a $143.00 target price for the company. Raymond James Financial dropped their price target on shares of Abbott Laboratories from $142.00 to $141.00 and set an "outperform" rating on the stock in a research report on Friday, July 18th. Finally, William Blair raised shares of Abbott Laboratories to a "strong-buy" rating in a research report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $145.22.

Get Our Latest Report on ABT

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of the business's stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.46% of the company's stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Featured Articles

• Five stocks we like better than Abbott Laboratories
• Transportation Stocks Investing
• Caterpillar Stock Hits All-Time High—Is There More Room to Run?
• What Are Dividend Champions? How to Invest in the Champions
• Berkshire-Backed Lennar Slides After Weak Q3 Earnings
• What is Put Option Volume?
• Analysts Turn Bullish on Hershey—Is Pepsi the Next Value Play?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Abbott Laboratories Right Now?

Before you consider Abbott Laboratories, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.

While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here